தடுப்பூசி வளர்ச்சி ப்ரோக்ர்யாம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Pfizer reports second-quarter 2021 results
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
Global COVID-19 Vaccines Market to Reach 9 7 Billion Doses
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.
POLITICO
Get the Prescription Pulse newsletter
Email
Sign Up
By signing up you agree to receive email newsletters or updates from POLITICO and you agree to our privacy policy and terms of service. You can unsubscribe at any time and you can contact us here. This sign-up form is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
With Katherine Ellen Foley, Rachel Roubein and Emily Martin.
On Tap The U.S. will send about 75 percent of its next batch of Covid shot donations to COVAX, with the rest going directly to allies and priority regions.
Following the completion of the spin-off of the Upjohn Business
(4) in the fourth quarter of 2020, Pfizer now operates as a focused innovative biopharmaceutical company engaged in the discovery, development, manufacturing, marketing, sales and distribution of biopharmaceutical products worldwide.
Revenues and expenses associated with the Upjohn Business
(4) for first-quarter 2020 have been recategorized as discontinued operations and excluded from Adjusted
(2) results. Pfizer’s Meridian subsidiary, the manufacturer of EpiPen and other auto-injector products, which had been reported within the results of the Upjohn Business
(4) in the first three quarters of 2020
, is now included within the Hospital therapeutic area for all periods presented.
5%
Below are specific updates on pipeline assets since our previous earnings announcement on October 27, 2020: Abrocitinib (PF-04965842) In November 2020, Pfizer announced positive top-line results from the fifth Phase 3 trial of abrocitinib, JADE REGIMEN, a 52-week study which investigated abrocitinib in patients 12 and older with moderate to severe atopic dermatitis (AD) following response to initial open label induction treatment with abrocitinib 200 mg. Patients were randomized into one of three arms: 200 mg, 100 mg or placebo. Both doses of abrocitinib met the primary endpoint, resulting in significantly fewer patients experiencing a loss of response requiring rescue treatment compared to those randomized to placebo. Both doses also met the key secondary endpoint of a larger percentage of patients maintaining an Investigator’s Global Assessment (IGA) response of clear or almost clear relative to placebo.
vimarsana © 2020. All Rights Reserved.